Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

NCT00854620 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Renal Cell
Kidney Disease
Kidney Cancer

Interventions

DRUG: Sorafenib

Sponsor

Stanford University